A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
NCT ID: NCT00136942
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
370 participants
INTERVENTIONAL
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
NCT00442325
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
NCT00644709
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
NCT00442845
Actual Use Trial of Atorvastatin Calcium 10 mg
NCT01964326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LDL-C \< 6.0 mmol/l
* Triglyceride level \< 5.0 mmol/l.
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Binningen, Basel-Landschaft, Switzerland
Pfizer Investigational Site
Liestal, Basel-Landschaft, Switzerland
Pfizer Investigational Site
Basel, Canton of Basel-City, Switzerland
Pfizer Investigational Site
Langenthal, Canton of Bern, Switzerland
Pfizer Investigational Site
Thun, Canton of Bern, Switzerland
Pfizer Investigational Site
Düdingen, Canton of Fribourg, Switzerland
Pfizer Investigational Site
Geneva, Canton of Geneva, Switzerland
Pfizer Investigational Site
Onex, Canton of Geneva, Switzerland
Pfizer Investigational Site
Pfaeffikon, Canton of Schwyz, Switzerland
Pfizer Investigational Site
Siebnen, Canton of Schwyz, Switzerland
Pfizer Investigational Site
Écublens, Canton of Vaud, Switzerland
Pfizer Investigational Site
Lausanne, Canton of Vaud, Switzerland
Pfizer Investigational Site
Prilly, Canton of Vaud, Switzerland
Pfizer Investigational Site
Unterägeri, Canton of Zug, Switzerland
Pfizer Investigational Site
Zug, Canton of Zug, Switzerland
Pfizer Investigational Site
Zurich, Canton of Zurich, Switzerland
Pfizer Investigational Site
Lugano, Canton Ticino, Switzerland
Pfizer Investigational Site
Malvaglia, Canton Ticino, Switzerland
Pfizer Investigational Site
Melide, Canton Ticino, Switzerland
Pfizer Investigational Site
Vezia, Canton Ticino, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.